Veracyte, Inc. (NasdaqGM: VCYT)
Health Care · Biotechnology · US
$43.60
+1.02% today · +24.7% 1Y
Veracyte, Inc. (NasdaqGM: VCYT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.47B and employs 755 people.
Over the last twelve months the share price has gained 24.7%, trading between 29.46 and 60.91.
Tweenvest scores Veracyte, Inc. across four factors: quality 76/100, value 53/100, growth 96/100. Its strongest factor is growth.
VCYT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.47B
- Revenue (TTM)
- $561.90M
- P/E
- 30.95
- EPS
- 1.39
- Dividend yield
- —
- Beta (5Y)
- 1.95
- 52-week high
- $60.91
- 52-week low
- $29.46
- Avg volume (3M)
- —
- Shares outstanding
- 80.39M
- Employees
- 755
- Next earnings
- —
About Veracyte, Inc.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
- ISIN
- US92337F1075
- Founded
- 2006
- Listed since
- Oct 29, 2013
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Hualan Biological Engineering Inc.SZSE: 002007 | $3.63B | CN¥13.34 | +1.75% |
| Celcuity Inc.NasdaqCM: CELC | $3.53B | $67.87 | -5.87% |
| Acrobiosystems Co.,Ltd.SZSE: 301080 | $3.52B | CN¥141.07 | +16.19% |
| IDEAYA Biosciences, Inc.NasdaqGS: IDYA | $3.50B | $36.06 | -0.55% |
| Walvax Biotechnology Co., Ltd.SZSE: 300142 | $3.39B | CN¥14.23 | +4.79% |
| Acadia Pharmaceuticals Inc.NasdaqGS: ACAD | $3.39B | $19.58 | -0.36% |
| Viking Therapeutics, Inc.NasdaqCM: VKTX | $3.33B | $27.73 | -2.84% |
| CareDx, Inc.NasdaqGM: CDNA | $3.26B | $62.21 | -1.32% |
Figures last refreshed Oct 4, 2026.